Patents by Inventor Mitsuyo Nagano

Mitsuyo Nagano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antithrombotic agent and anti-von willebrand factor monoclonal antibody
    Patent number: 6793920
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: September 21, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Antithrombotic agent and anti-von willebrand factor monoclonal antibody
    Publication number: 20020028204
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Application
    Filed: August 8, 2001
    Publication date: March 7, 2002
    Applicant: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Antithrombotic agent and anti-von willebrand factor monoclonal antibody
    Patent number: 6280731
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: August 28, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Antithrombotic agent and anti-von Willebrand factor monoclonal antibody
    Patent number: 5916805
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: June 29, 1999
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Peptide having anti-thrombus activity and method of producing the same
    Patent number: 5856126
    Abstract: A multimer peptide from a snake venom has an activity to inhibit binding between von Willebrand factor and platelets. The multimer peptide is used to obtain a single strand peptide which does not substantially cause decrease in platelets at a minimum dose for exhibiting the activity in vivo. The single strand peptide is obtained by allowing the multimer peptide to exist together with a protein-denaturing agent, and glutathione and/or cysteine, and thereby disconnecting disulfide bonds between peptide chains for constituting the multimer peptide while substantially preserving disulfide bonds within the peptide chains. Alternatively, the single strand peptide, a mutant thereof, or a part thereof is produced by genetic engineering techniques by using genes coding for them.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: January 5, 1999
    Assignee: Ajinomoto Co., Inc.
    Inventors: Naoyuki Fukuchi, Hiroshi Yamamoto, Mitsuyo Nagano, Morikazu Kito, Akiko Tanaka, Koichi Ishii, Tsuyoshi Kobayashi, Ryota Yoshimoto